Home › Trials › NCT04571658

NEPTUNE Match: Personalized matching of patients to kidney treatment options

Implementing Precision Medicine for Glomerular Diseases in the Nephrotic Syndrome Study Network (NEPTUNE)

Not applicable Interventional University of Michigan · NCT04571658

This project will try a system that matches people in the NEPTUNE cohort who have nephrotic syndromes or related kidney diseases with suitable clinical trials and shares those matches with patients and their doctors.

Quick facts

PhaseNot applicable
Study typeInterventional
Enrollment375 (estimated)
Ages1 Year to 80 Years
SexAll
SponsorUniversity of Michigan Academic / other
Locations16 sites (Atlanta, Georgia and 15 other locations)
Trial IDNCT04571658 on ClinicalTrials.gov

What this trial studies

NEPTUNE Match is a prospective, open-label effort that recruits participants from the NEPTUNE observational cohort and creates patient-specific trial match assessments using existing clinical and molecular data reviewed by the NEPTUNE Molecular Nephrology Board. The program will establish and test a communication framework to share disease-to-drug-mechanism matches with treating clinicians and patients. It will then compare kidney health outcomes retrospectively between subjects who enrolled in trials aligned with their match and those with misaligned or unknown match alignment. The goal is to determine if structured matching and targeted communication improves trial alignment and downstream outcomes.

Who should consider this trial

Good fit: Ideal candidates are individuals already enrolled in the NEPTUNE observational cohort with nephrotic syndrome or related diagnoses who receive regular nephrology care at a participating NEPTUNE site and meet age and trial-specific eligibility.

Not a fit: People not enrolled in NEPTUNE, those who do not speak English or Spanish, or those outside the age ranges or other criteria of available partnering trials are unlikely to benefit from NEPTUNE Match.

Why it matters

Potential benefit: If successful, patients may have improved access to clinical trials that better match their disease mechanism, potentially increasing the chance of benefiting from targeted therapies.

How similar studies have performed: Matching and precision-referral programs have shown promise in oncology and other fields, but applying biomarker-driven trial matching to nephrotic syndromes is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

1. Consented and eligible participants in the biopsied or non-biopsied cohorts of the NEPTUNE observational study
2. Must be potentially eligible for the NEPTUNE Match partnering trials (e.g. if no trial is enrolling a participant under age 6, those under 6 are not eligible).

   Note: NEPTUNE Match partnering trials and associated eligibility criteria are expected to be dynamic and change as trial protocols are developed, activated, and amended.
3. Regular nephrology healthcare provided at a NEPTUNE study site.
4. Willing and able to consent, and as appropriate assent, to participate in NEPTUNE Match

Exclusion Criteria:

Currently non-NEPTUNE observational study participants are not eligible to be matched to a clinical trial using these biomarker assessments.

Exclusion Criteria:

1\. Non-English or non-Spanish speaking

Where this trial is running

Atlanta, Georgia and 15 other locations

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions Nephrotic Syndrome in ChildrenFocal Segmental GlomerulosclerosisMinimal Change DiseaseMinimal Change Nephrotic SyndromeMembranous NephropathyFSGSMCDMCD - Minimal Change Disease
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.